Literature DB >> 1570838

DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

C F Bartels1, F S Jensen, O Lockridge, A F van der Spek, H M Rubinstein, T Lubrano, B N La Du.   

Abstract

Genomic DNA from two families exhibiting the K-variant phenotype of serum butyrylcholinesterase was amplified by PCR and sequenced to determine the molecular basis of this variant. The K-variant phenotype was found to be associated with a DNA transition from guanine to adenine at nucleotide 1615, which caused an amino acid change from alanine 539 to threonine (GCA----ACA; Ala539----Thr). There was a 30% reduction of serum butyrylcholinesterase activity associated with this mutation. Amplification and sequencing of DNA from a random sample of 47 unrelated people gave a frequency of .128 for the K-variant allele. Thus, 1 person in 63 should be homozygous for the K-variant, making the K-variant the most common butyrylcholinesterase variant. The K-variant mutation was also found to be present in 17 (89%) of 19 butyrylcholinesterase genes containing the point mutation which causes the atypical phenotype of butyrylcholinesterase (GAT----GGT; Asp70----Gly). The presence of the K-variant in the same molecule as the atypical variant does not contribute to the qualitative change in the atypical enzyme, but it most likely accounts for the approximately one-third reduction in Vmax of butyrylcholinesterase activity in atypical serum. Two additional point mutations located in noncoding regions of the gene were also observed to be in linkage disequilibrium with the K-variant mutation. As many as four different point mutations have been identified within a single butyrylcholinesterase gene. Inhibition tests of the enzyme in plasma are usually used to distinguish the K-variant from the usual enzyme when the former is present with the heterozygous atypical variant (AK phenotype vs. UA phenotype). Inhibition tests were performed on plasma enzyme from the four possible genotypic combinations of the heterozygous atypical mutation with or without the K-variant mutation on either allele; we found that the AK phenotype was caused by three genotypes (A/K, AK/K, and U/A) and that the UA phenotype was caused by two genotypes (U/A and U/AK).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1570838      PMCID: PMC1682596     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  40 in total

1.  HARRIS AND WHITTAKER'S PSEUDOCHOLINESTERASE VARIANT WITH INCREASED RESISTANCE TO FLUORIDE. A STUDY OF FOUR FAMILIES AND THE IDENTIFICATION OF THE HOMOZGOTE.

Authors:  J LIDDELL; H LEHMANN; D DAVIES
Journal:  Acta Genet Stat Med       Date:  1963

2.  On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers.

Authors:  W KALOW; N STARON
Journal:  Can J Biochem Physiol       Date:  1957-12

3.  A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers.

Authors:  W KALOW; K GENEST
Journal:  Can J Biochem Physiol       Date:  1957-06

4.  The relation between dose of succinylcholine and duration of apnea in man.

Authors:  W KALOW; D R GUNN
Journal:  J Pharmacol Exp Ther       Date:  1957-06       Impact factor: 4.030

5.  The familial incidence of low pseudocholinesterase level.

Authors:  H LEHMANN; E RYAN
Journal:  Lancet       Date:  1956-07-21       Impact factor: 79.321

6.  A comparison of optical and manometric methods for the assay of human serum cholinesterase.

Authors:  W KALOW; H A LINDSAY
Journal:  Can J Biochem Physiol       Date:  1955-07

7.  E1j, a quantitative variant at cholinesterase locus 1: immunological evidence.

Authors:  H M Rubinstein; A A Dietz; T Lubrano; P J Garry
Journal:  J Med Genet       Date:  1976-02       Impact factor: 6.318

8.  Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.

Authors:  B N La Du; C F Bartels; C P Nogueira; M Arpagaus; O Lockridge
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

9.  The butyrylcholinesterase gene (BCHE) at 3q26.2 shows two RFLPs.

Authors:  P J McAlpine; M Dixon; P W Allderdice; O Lockridge; B N La Du
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

10.  DNA mutations associated with the human butyrylcholinesterase J-variant.

Authors:  C F Bartels; K James; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

View more
  41 in total

Review 1.  Genetic risk factors in Alzheimer's disease.

Authors:  L Tilley; K Morgan; N Kalsheker
Journal:  Mol Pathol       Date:  1998-12

2.  BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.

Authors:  Caterina Chianella; Daniela Gragnaniello; Pierpaolo Maisano Delser; Maria Francesca Visentini; Elisabetta Sette; Maria Rosaria Tola; Guido Barbujani; Silvia Fuselli
Journal:  Eur J Clin Pharmacol       Date:  2011-06-01       Impact factor: 2.953

3.  Interaction between estrogen receptor-alpha and butyrylcholinesterase genes modulates Alzheimer's disease risk.

Authors:  Onofre Combarros; José Antonio Riancho; Jana Arozamena; Ignacio Mateo; Javier Llorca; Jon Infante; Pascual Sánchez-Juan; María Teresa Zarrabeitia; José Berciano
Journal:  J Neurol       Date:  2007-04-06       Impact factor: 4.849

4.  Mutation at codon 322 in the human acetylcholinesterase (ACHE) gene accounts for YT blood group polymorphism.

Authors:  C F Bartels; T Zelinski; O Lockridge
Journal:  Am J Hum Genet       Date:  1993-05       Impact factor: 11.025

5.  Large-scale studies of the functional K variant of the butyrylcholinesterase gene in relation to Type 2 diabetes and insulin secretion.

Authors:  A Johansen; E-M D Nielsen; G Andersen; Y H Hamid; D P Jensen; C Glümer; T Drivsholm; K Borch-Johnsen; T Jørgensen; T Hansen; O Pedersen
Journal:  Diabetologia       Date:  2004-07-17       Impact factor: 10.122

6.  Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder.

Authors:  Sadaf Munir; Rabia Habib; Sliha Awan; Nazia Bibi; Arooj Tanveer; Sajida Batool; Syed M Nurulain
Journal:  J Mol Neurosci       Date:  2019-02-01       Impact factor: 3.444

7.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

8.  Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity.

Authors:  Ivo F Panhuizen; Marc M J Snoeck; Soledad Levano; Thierry Girard
Journal:  Case Rep Med       Date:  2010-06-17

9.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

10.  Childhood brain tumors, residential insecticide exposure, and pesticide metabolism genes.

Authors:  Susan Searles Nielsen; Roberta McKean-Cowdin; Federico M Farin; Elizabeth A Holly; Susan Preston-Martin; Beth A Mueller
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.